Evogene Ltd.
EVGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.08 | -0.00 | -3.87 |
| FCF Yield | -190.79% | -58.27% | -86.14% | -3.80% |
| EV / EBITDA | -0.53 | -1.25 | -0.44 | -23.13 |
| Quality | ||||
| ROIC | -65.04% | -58.56% | -58.00% | -44.75% |
| Gross Margin | 39.81% | 24.80% | -105.91% | -222.69% |
| Cash Conversion Ratio | 1.09 | 0.83 | 0.79 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 71.92% | 82.36% | 17.22% | 7.29% |
| Free Cash Flow Growth | 9.10% | 10.01% | 2.79% | -26.57% |
| Safety | ||||
| Net Debt / EBITDA | 0.16 | 0.40 | 0.63 | 1.07 |
| Interest Coverage | -175.27 | -154.33 | -123.30 | -78.14 |
| Efficiency | ||||
| Inventory Turnover | 2.82 | 55.80 | 6.09 | 32.62 |
| Cash Conversion Cycle | 105.88 | -95.05 | 125.24 | 294.01 |